The partners will identify patients with gastrointestinal or endometrial cancers who may benefit from immune checkpoint inhibitor therapy using Biotype's technology.
The company will rely more on distribution partners in Europe for its Unyvero product line while continuing highly targeted commercialization efforts in the US.
The test is a 15-biomarker quantitative PCR panel used to stratify patients with Crohn's disease and ulcerative colitis based on the severity of their illness.
